Structure Therapeutics (NASDAQ:GPCR) Shares Gap Down to $32.65

Structure Therapeutics Inc. (NASDAQ:GPCRGet Free Report)’s stock price gapped down prior to trading on Monday . The stock had previously closed at $32.65, but opened at $31.35. Structure Therapeutics shares last traded at $32.07, with a volume of 64,390 shares changing hands.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on GPCR shares. Jefferies Financial Group initiated coverage on shares of Structure Therapeutics in a report on Thursday, May 25th. They issued a “buy” rating and a $41.00 price target on the stock. Piper Sandler initiated coverage on shares of Structure Therapeutics in a research report on Thursday, July 27th. They issued an “overweight” rating and a $58.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of “Buy” and a consensus price target of $44.40.

Get Our Latest Analysis on GPCR

Structure Therapeutics Price Performance

The business’s 50-day simple moving average is $30.91 and its two-hundred day simple moving average is $28.72.

Structure Therapeutics (NASDAQ:GPCRGet Free Report) last released its quarterly earnings results on Thursday, August 10th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Sell-side analysts expect that Structure Therapeutics Inc. will post -0.88 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently bought and sold shares of GPCR. BVF Inc. IL acquired a new stake in Structure Therapeutics in the 1st quarter valued at about $41,632,000. FMR LLC acquired a new stake in Structure Therapeutics in the 1st quarter valued at about $29,724,000. Monashee Investment Management LLC raised its holdings in Structure Therapeutics by 706.5% in the 2nd quarter. Monashee Investment Management LLC now owns 1,370,991 shares of the company’s stock valued at $22,755,000 after acquiring an additional 1,200,991 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Structure Therapeutics in the 1st quarter valued at about $25,046,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Structure Therapeutics in the 1st quarter valued at about $18,711,000. Institutional investors and hedge funds own 46.12% of the company’s stock.

Structure Therapeutics Company Profile

(Get Free Report)

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Featured Articles

Receive News & Ratings for Structure Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Structure Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.